ALNYLAM UK LIMITED 2020 PATIENT ORGANIZATION SUPPORT

Alnylam UK Limited has voluntarily agreed to abide by the PMCPA Code of Practice and supports the efforts of the ABPI to increase transparency in the pharmaceutical industry.

In accordance with Clause 27 of the PMCPA Code of Practice for the Pharmaceutical Industry, this document lists UK patient organizations to which Alnylam provided support to in 2020.

For financial support, the date of payment has been used to determine the year in which support will be declared (e.g., if an agreement was signed in December 2020 but the payment for this agreement was made in January 2021, the support will be declared as having taken place in 2021 in the disclosure that will be made in 2022).

Metabolic Support UK

- Metabolic Support UK applied for an educational grant and was awarded £15,000

ATTR Amyloidosis Patients’ Association

- The ATTR Amyloidosis Patients’ Association applied for an educational grant and was awarded £25,000

British Porphyria Association

- Alnylam was a sponsor of a British Porphyria Association patient meeting, providing £2,000

- Alnylam contracted with a member of the British Porphyria Association in two advisory boards, as an educational speaker at an Alnylam company meeting, and participated in a disease awareness podcast. The total cost of these activities (including fees & expenses) was £1,751.75

UK ATTR Amyloidosis Patients’ Association

- Alnylam contracted with a member of the UK ATTR Amyloidosis Patients’ Association in two advisory boards as an educational speaker at an Alnylam company event. The total cost of these activities (including fees & expenses) was £1,946.77

- Alnylam contracted with a second member of the UK ATTR Amyloidosis Patients’ Association as an educational speaker at an Alnylam company event, an advisory board and participated in a disease awareness video. The total cost (including fees & expenses) was £1945.29

Genetic Disorders UK

- Alnylam provided funding of $5,000 to support Genetic Disorders UK’s “Building Communities and Improving Patient Engagement” programme